الفهرس 
BUDD-CHIARI SYNDROMEOnly 14 pages are availabe for public view
 |  | from | 196 |  |  |
| | | from | 196 | | |
Abstract
Budd -Chiari syndrome (BCS) is a rare but potentially life threatening hepatic disorder that results from obstruction of the hepatic venous outflow tract. Obstruction can occur at any level from the hepatic venules to the right atrium
According to the etiology, BCS can be classified as primary (due to intrinsic intraluminal thrombosis or webs) or secondary (due to intraluminal invasion by a parasite or malignant tumor or extraluminal compression by an abscess, cyst or solid tumor)
The goals of treatment are to prevent extension of thrombosis in the hepatic veins and to alleviate venous obstruction in order to decrease hepatic congestion. Few patients respond to medical treatment (anticoagulation with or without thrombolytic therapy, diuretics). However, most of patients need more invasive procedures to restore the hepatic blood flow including percutaneous angioplasty with or without stenting, transjugular intrahepatic portosystemic shunt (TIPS) or shunt surgery.
This retrospective study aims to assess the clinical and technical efficacy and the short-term outcome of the medical and endovascular therapy in BCS patients with myeloproliferative disorder as an underlying aetiology.